Sign in
SuspendedPhase 1

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Key facts

Who runs it
Innovent Biologics (Suzhou) Co. Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 1
People taking part
120 people, planned
Started
30 Sept 2020
Ended
20 Aug 2024
Type of study
Interventional
Treatments tested
  • IBI188+azacitidine
Record updated
16 February 2023
Why it stopped
Suspended for changes in development strategy

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • MDS subjects with higher risk
  • Age ≥ 18 years old
  • Eastern Cooperative Oncology Group score of 0~1
  • Not suitable for or refuse to receive HSCT
  • Newly diagnosed MDS subjects
  • Adequate organ function
  • Subjects should take effective contraceptive measures
  • Must sign the Informed Consent Form (ICF), and be able to follow all study procedures

Who cannot take part

  • Therapy-related MDS (t-MDS), myeloproliferative neoplasm (MPN)- transformed MDS,MDS/MPN
  • Subjects who have received chemotherapy
  • Prior exposure to any anti-CD47 or anti-SIRPα agents
  • Subject who has transformed from MDS to AML
  • MDS subjects with lower risk
  • Subjects participating in another interventional clinical study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome

The group in the trial

  • IBI188+azacitidineTreatment being tested

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome
Record updated
16 February 2023